Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 649-663

  Colombo, Jucimara ^a   Fachel, Ângela A ^b   Calmon, Marilia De Freitas ^a   Cury, Patrícia Maluf ^c   Fukuyama, Érica Erina ^d   Tajara, Eloiza Helena ^c   Cordeiro, José Antônio ^c   Verjovski Almeida, Sergio ^b   Reis, Eduardo M ^b   Rahal, Paula ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^d Instituto do Cancer Dr Arnaldo   (Brazil)

Author keywords

CDNA microarray; Cystatin B; Gene expression; Larynx carcinoma; Real time RT PCR

Indexed keywords

ADENYLATE CYCLASE 6; AMINO TERMINAL ENHANCER OF SPLIT ISOFORM B; AMYOTROPIC LATERAL SCLEROSIS 2 CHROMOSOME REGION 3; APOPTOSIS SIGNAL REGULATING KINASE 1; CISPLATIN RESISTANCE RELATED PROTEIN 9; CYSTATIN B; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MOLECULAR MARKER; SUMO 1 PROTEIN; TISSUE PLASMINOGEN ACTIVATOR 2; TUMOR MARKER; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ZINC FINGER PROTEIN 706;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DNA REPAIR; ENZYME INHIBITION; EXPRESSED SEQUENCE TAG; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; MALE; MOLECULAR PROBE; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 64949112729     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000268     Document Type: Article

References (86)

1. Lothaire P, de Azambuja E, Dequanter D, et al: Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28: 256-269, 2006.
2. Döbrossy L: Epidemiolgy of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24: 9-17, 2005.
3. Chung CH, Levy S and Yarbrough WG: Clinical applications of genomics in head and neck cancer. Head Neck 28: 360-368, 2006.
4. INCA - Instituto Nacional do Câncer, Ministŕio da Saúde. Estimativa da incidência e mortalidade por câncer no Brasil, Rio de Janeiro. http://www.inca.org.br, 2008.
5. Hunter KD, Parkinson EK and Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135, 2005.
6. Ragin CC, Modugno F and Gollin SM: The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86: 104-114, 2007.
7. Choi P and Chen C: Genetic expression profiles and biology pathway alterations in head and neck squamous cell carcinoma. Cancer 104: 1113-1128, 2005.
8. Kim MM and Califano JA: Molecular pathology of head and neck cancer. Int J Cancer 112: 545-553, 2004.
9. Angadi PV and Krishnapillai R: Cyclin D1 expression in oral squamous cell carcinoma and verrucous carcinoma: correlation with histological differentiation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: 30-35, 2007.
10. Kalyankrishna S and Grandis JR: Epidermal growth factor receptor biology in head and neck. J Clin Oncol 24: 2666-2672, 2006.
11. Ruíz-Godoy RLM, Garcia-Cuellar CM, Herrera Gonzalez NE, et al: Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J Exp Clin Cancer Res 25: 73-78, 2006.
12. Papakosta V, Vairaktaris E, Vylliotis A, et al: The co-expression of c-myc and p53 increases and reaches a plateau early in oral oncogenesis. Anticancer Res 26: 2957-2962, 2006.
13. Smith EM, Wang D, Kim Y, Rubenstein LM, Lee JH, Haugen TH and Turek LP: p16(INK4a) Expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol 44: 133-149, 2007.
14. Keum KC, Chung EJ, Koom WS, et al: Predictive value of p53 and PCNA expression for occult neck metastases in patients with clinically node-negative oral tongue cancer. Otolaryngol Head Neck Surg 135: 858-864, 2006.
15. Hirai T, Hayashi K, Takumida M, Ueda T, Hirakawa K and Yajin K: Reduced expression of p27 is correlated with progression in precancerous lesions of the larynx. Auris Nasus Larynx 30: 163-168, 2003.
16. Nemes JA: p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med 34: 274-279, 2005.
17. Gleich LL and Salamone FN: Molecular genetics of head and neck cancer. Cancer Control 9: 369-378, 2002.
18. Thomas GR, Nadiminti H and Regalado J: Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Path 86: 347-363, 2005.
19. Belbin TJ, Singh B, Smith RV, Socci ND, et al: Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg 131: 10-18, 2005.
20. Squire JA, Bayani J, Luk C, et al: Molecular cytogenetic analysis of head and neck squamous cell carcinoma: by comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck 24: 874-887, 2002.
21. Al Moustafa AE, Alaoui-Jamali MA, Batist G, et al: Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 21: 2634-2640, 2002.
22. Carinci F, Arcelli D, Lo Muzio L, et al: Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma. Transl Res 150: 233-245, 2007.
23. Reis EM, Ojopi EP, Alberto FL, et al: Large-scale transcriptome analyses reveal new marker candidates of head, neck, and thyroid cancer. Cancer Res 65: 1693-1699, 2005.
24. Knuutila S, Autio K and Aalto Y: Online access to CGH data of DNA sequence copy number changes. Am J Pathol 157: 689, 2000.
25. Rozen S and Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386, 2000.
26. International Union Against Cancer (UICC): TNM classification of malignant tumours, 6th edition. Wiley-Liss, New York, 2002.
27. Peixoto BR, Vêncio RZ, Egidio CM, Mota-Vieira L, Verjovski- Almeida S and Reis EM: Evaluation of reference-based twocolor methods for measurement of gene expression ratios using spotted cDNA microarrays. BMC Genomics 7: 35, 2006.
28. Quackenbush J: Microarray data normalization and transformation. Nat Genet 32: 496-501, 2002.
29. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
30. Maglot D, Ostell J, Pruitt KD and Tatusova T: Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 35: D26-D31, 2007.
31. Iseli C, Jongeneel CV and Bucher P: ESTScan: a program for detecting, evaluating, and reconstructing potential coding regions in EST sequences. Proc Int Conf Intell Syst Mol Biol: 138-148, 1999.
32. Vokes EE and Stenson KM: Therapeutic options for laryngeal cancer. N Engl J Med 349: 2087-2089, 2003.
33. Birney E, Stamatoyannopoulos JA, Dutta A, et al: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816, 2007.
34. Nakaya HI, Amaral PP, Louro R, et al: Genome mapping and expression analyses of human intronic noncoding RNAs reveal tissue-specific patterns and enrichment in genes related to regulation of transcription. Genome Biol 8: R43, 2007.
35. Reis EM, Nakaya HI, Louro R, et al: Antisense intronic noncoding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene 23: 6684-6692, 2004.
36. Hedge PS, White IR and Debouck C: Interplay of transcriptomics and proteomics. Curr Opin Biotechnol 14: 647-651, 2003.
37. Liew KJL and Chow VTK: Microarray and real-time RT-PCR analysis of a novel set of differentially expressed human genes in ECV304 endothelial-like cells infected with dengue virus type 2. J Virol Meth 131: 47-57, 2006.
38. Celano M, Arturi F, Presta I, et al: Expression cyclase types III and VI in human hyperfunctioning thyroid nodules. Mol Cell Endocrinol 203: 129-135, 2003.
39. Tetsuka T, Uranishi H, Imai H, et al: Inhibition of nuclear factor-kappaB-mediated transcription by association with the amino-terminal enhancer of split, a Groucho-related protein lacking WD40 repeats. J Biol Chem 275: 4383-4390, 2000.
40. Chang AA and Waes CV: Nuclear factor-kappaß as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv Otorhinolaryngol 62: 92-102, 2005.
41. Loercher A, Lee TL and Ricker JL: Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64: 6511-6523, 2004.
42. Lepourcelet M and Shivdasani RA: Characterization of a novel mammalian Groucho isoform and its role in transcriptional regulation. J Biol Chem 277: 47732-47740, 2002.
43. Wong NACS and Pignatelli M: β-Catenin - A Linchpin in colorectal carcinogenesis. Am J Pathol 160: 389-401, 2002.
44. Brickley K: GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain proteins: association in vivo and in vitro with kinesin. J Biol Chem 280: 14723-14732, 2005.
45. Hadano S, Hand CK, Osuga H, et al: A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29: 166-173, 2001.
46. Keppler D: Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235: 159-176, 2006.
47. Fehrenbacher M, Gyrd-Hansen B, Poulsen U, Felbor T, Kallunki T and Boes M: Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 64: 5301-5310, 2004.
48. Joyce JA, Baruch A, Chehade K, et al: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453, 2004.
49. Zheng X, Chou PM, Mirkin BL and Rebaa A: Senescenceinitiated reversal of drug resistance: specific role of cathepsin L. Cancer Res 64: 1773-1780, 2004.
50. Shiraishi T, Mori M, Tanaka S, Sugimashi K and Akiyoshi T: Identification of cystatin B in human esophageal carcinoma using displays in which the gene expression is related to lymph-node metastasis. Int J Cancer 79:175-178, 1998.
51. Levicar N, Kos J, Blejec A, Golouch R, Vrhovec I, Frkovic-Grazio S and Lah TT: Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinopathological data of breast carcinoma patients. Cancer Detect Prev 26: 42-49, 2002.
52. Mirtti T, Alanen K, Kallajoki M, Rinne A and Soderstrom KO: Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Prostate 54: 290-298, 2003.
53. Trinkaus M, Vranic A, Dolene VV and Lah TT: Cathepsins B and L and their inhibitors stefin B and Cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers 20: 50-59, 2005.
54. Lin YW and Yang JL: Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferatin signaling. J Biol Chem 281: 915-926, 2006.
55. Li M, Zhou J, Ge Y, Matherly LH and Wu GS: The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 278: 41059-41068, 2003.
56. Denkert C, Schmitt WD and Berger S: Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 102: 507-513, 2002.
57. Rauhala HE, Porkka KP, Tolonen TT, Martikainen PM, Tammela TLJ and Visakorpi T: Dual-specificity phosphatase 1 and serum/ glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer 117: 738-745, 2005.
58. Tomioka H, Morita K, Hasegawa S and Omura K: Gene expression analysis by cDNA microarray in oral squamous cell carcinoma. J Oral Pathol Med 35: 206-211, 2006.
59. Unoki M and Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20: 4457-4465, 2001.
60. Abraham SM and Clark AR: Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 34: 1018-1023, 2006.
61. Hardy K, Mansfield L, Mackay A, et al: Transcriptional networks and cellular senescence in human mammary fibroblasts. Mol Biol Cell 16: 946-953, 2005.
62. Subramanian RR, Zhang H, Wang H, Ichijo H, Miyashita T and Fu H: Interaction of apoptosis signal-regulating kinase 1 with isoforms of 14-3-3 proteins. Exp Cell Res 294: 581-591, 2004.
63. Mizumura K, Takeda K, Hashimoto S, Horie T and Ichijo H: Identification of Op18/stathmin as a potential target of ASK1-p38 MAP kinase cascade. J Cell Physiol 206: 363-370, 2006.
64. Nagai H, Noguchi T, Takeda K and Ichijo H: Pathophysiological roles of ASK1-MAP kinase signaling pathways. J Biochem Mol Biol 40: 1-16, 2007.
65. Dasgupta P, Betts V, Rastogi S, et al: Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein. J Biol Chem 279: 38762-38769, 2004.
66. Kherrouche Z, Blais A, Ferreira E, De Launoit Y and Monté D: ASK-1 (apoptosis signal-regulating kinase 1) is a direct E2F target gene. Biochem J 396: 547-556, 2006.
67. Shim BC, Kang BH, Hong YK, et al: The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth. Biochem Biophys Res Commun 327:1155-1162, 2005.
68. Pepper MS: Role of matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21: 1104-1117, 2001.
69. Ferrier CM, Suciu S, van Geloof WL, et al: High t-PA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 83: 1351-1359, 2000.
70. Chappuis PO, Dieterich B, Scietta V, Lohse C, Bonnefoi H, Remadi S and Sapino AP: Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 19: 2731-2738, 2001.
71. Reijerkerk A, Voest EE and Gebbink MFGB: No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 36: 16695-16705, 2000.
72. Gingras D, Nyalendo C, Di Tomasso G, Annabi B and Béliveau R: Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. Biochem Biophys Res Commun 16: 205-212, 2004.
73. Gingras D, Labelle D, Nyalendo C, Boivin D, Demeule M, Barthomeuf C and Béliveau R: The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity. Invest New Drugs 22: 17-26, 2004.
74. Yamamoto, K, Okamoto A, Isonishi S, Ochiai K and Ohtake Y: A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun 280: 1148-1154, 2001.
75. Asakura T, Imai A, Ohkubo-Uraoka N, et al: Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep 14: 601-607, 2005.
76. Gill G: SUMO and ubiquitin in the nucleus: Different functions, similar mechanisms? Genes Dev 18: 2046-2059, 2004.
77. Chen A, Wang PY, Yang YC, et al: SUMO regulates the cytoplasmonuclear transport of its target protein Daxx. J Cell Biochem 98: 895-911, 2006.
78. Li W, Hesabi B, Babbo A, et al: Regulation of double-strand break-induced mammalian homologous recombination by UBL1, a RAD51-interacting protein. Nucleic Acids Res 28: 1145-1153, 2000.
79. Lee YS, Jang MS, Lee JS, Choi EJ and Kim E: SUMO-1 represses apoptosis signal-regulating kinase 1 activation through physical interaction and not through covalent modification. EMBO Rep 6: 949-955, 2005.
80. Lichtenfels R, Kellner R, Atkins D, et al: Identification of metabolic enzymes in renal cell carcinoma utilizing Proteomex analyses. Biochim Biophys Acta 1646: 21-31, 2003.
81. Xiang, Z: A novel human zinc finger protein ZNF540 interacts with MVP and inhibits transcriptional activities of the ERK signal pathway. Biochem Biophys Res Commun 347: 288-296, 2006.
82. Zhao Y, Zhou L, Liu B, et al: ZNF325, a novel human zinc finger protein with a RBaK-like RB-binding domain, inhibits AP-1- and SRE-mediated transcriptional activity. Biochem Biophys Res Commun 346: 1191-1199, 2006.
83. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
84. Rosenthal EL and Matrisian LM: Matrix metalloproteases in head and neck cancer. Head Neck 28: 639-648, 2006.
85. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M and Rao JS: RNAi-mediated inhibition of cathepisin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23: 8486-8496, 2004.
86. Kos J, Werle B, Lah T and Brunner N: Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15: 84-89, 2000.